Cell-mediated immune responses to complex and single mycobacterial antigens in tuberculosis patients with diabetes

Medical Principles and Practice

Volumn 17, Issue 4, 2008, Pages 325-330

  Mustafa, Abu S ^a   El Shamy, Abdulsalam M ^b   Madi, Nada M ^a   Amoudy, Hanady A ^a   Al Attiyah, Rajaa ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MINISTRY OF HEALTH   (Kuwait)

Author keywords

Antigens; Cellular immune responses; Diabetes; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

MYCOBACTERIUM ANTIGEN;

ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; TUBERCULOSIS;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNITY, CELLULAR; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS;

EID: 44849118238     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000129614     Document Type: Article

References (25)

1. Borgdorff MW, Floyd K, Broekmans JF: Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ 2002;80:217-227.
2. Dye C: Global epidemiology of tuberculosis. Lancet 2006;36:938-940.
3. Boutayeb A: The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg 2006;100:191-199.
4. Boutayeb A, Boutayeb S: The burden of non communicable diseases in developing countries. Int J Equity Health 2005;4:2.
5. Broxmeyer L: Diabetes mellitus, tuberculosis and the mycobacteria: two millenia of enigma. Med Hypotheses 2005;65:433-439.
6. Mustafa AS: Development of improved vaccines against tuberculosis. Med Princ Pract 1997;6:55.
7. Mustafa AS, Oftung F: Identification of mycobacterial recombinant antigens recognized by human T cells. Med Princ Pract 1997;6:57-65.
8. Mustafa AS: Development of new vaccines and diagnostic reagents against tuberculosis. Mol Immunol 2002;39:113-119.
9. Mustafa AS: Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med Princ Pract 2005;14(suppl 1):27-34.
10. Mustafa AS: Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb) 2005;85:367-376.
11. Al-Attiyah R, Shaban FA, Wiker HG, Oftung F, Mustafa AS: Synthetic peptides identify promiscuous human Th1 cell epitopes of the secreted mycobacterial antigen MPB70. Infect Immun 2003;71:1953-1960.
12. Amoudy HA, AI-Asmer ABH, Abul AT, Mustafa AS: Evaluation of complex and defined antigens of Mycobacterium tuberculosis in an IgG specific ELISA for the diagnosis of tuberculosis. Med Princ Pract 1997;6:103-109.
13. Al-Attiyah R, Mustafa AS, Abal AT, Madi NM, Andersen P: Restoration of mycobacterial antigen-induced proliferation and interferon-γ responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. FEMS Immunol Med Microbiol 2003;38:249-256.
14. Mustafa AS, Amoudy HA, Oftung F, Wiker HG, Abal AT, Ravn P, Andersen P: Comparison of antigen-specific T-cell responses of tuberculosis patients using complex or single antigens of Mycobacterium tuberculosis. Scand J Immunol 1998;48:535-543.
15. Al-Attiyah R, Mustafa AS: Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1 cell peptides in a novel 24-kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand J Immunol 2004;59:16-24.
16. Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AM, Dalemans W, Skeiky YAW: In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 2004;138:139-144.
17. Mustafa AS, Abal AT, Shaban F, El-Shamy AM, Amoudy HA: HLA-DR binding prediction and experimental evaluation of mycolyl transferase (Ag85B), a major secreted antigen of Mycobacterium tuberculosis. Med Princ Pract 2005;14:140-146.
18. Mustafa AS: Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis. Curr Pharm Biotechnol 2001;2:157-173.
19. Mustafa AS: Progress towards the development of new anti-tuberculosis vaccines; in Smithe LT (ed): Focus on Tuberculosis Research. New York, Nova Science Publishers, 2005, pp 47-76.
20. Lalvani A: Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007;131:1898-1906.
21. Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R: ESAT-6 proteins: protective antigens and virulence factors? Trends Microbiol 2004;12:500-508.
22. Mantegani P, Piana F, Codecasa L, Galli L, Scarpellini P, Lazzarin A, Cirillo D, Fortis C: Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection. Clin Med Res 2006;4:266-272.
23. Shinde SR, Chiplunkar SV, Butlin R, Samson PD, Deo MG, Gangal SG: Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients. Int J Lepr Other Mycobact Dis 1993;61:51-58.
24. Mustafa AS, Al-Attiyah R: Mycobacterium tuberculosis antigens and peptides as new vaccine candidates and immunodiagnostic reagents against tuberculosis. Kuw Med J 2004;36:171-176.
25. Renshaw PS, Panagiotidou P, Whelan A, Gordon SV, Hewinson RG, Williamson RA, Carr MD: Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6*CFP-10 complex: implications for pathogenesis and virulence. J Biol Chem 2002;277:21598-21603.